Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FCFJ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,250
Award facts
- Contract value 100% obligated
- $21,250.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
On November 5, 2025, the Defense Logistics Agency awarded a delivery order valued at $21,250.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml syringes. This firm fixed-price delivery order carries an ultimate completion date of November 6, 2025, and was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. was selected as the awardee based on its established performance as a critical supplier within the federal pharmaceutical supply chain and its registration in the System for Award Management since July 2001.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 with completion through December 31, 2036, and is structured to enable the contractor to serve as a critical pharmaceutical supplier for Department of Defense healthcare operations globally. The PPV-G GEN V program represents a $30.3 billion acquisition strategy encompassing multiple regional prime vendor contractors, authorizing firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FCFJ8?
SPE2DR26FCFJ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 5, 2025.
How much is contract SPE2DR26FCFJ8 worth?
The government has obligated $21,250 on SPE2DR26FCFJ8.
Is contract SPE2DR26FCFJ8 an order under another contract?
Yes. SPE2DR26FCFJ8 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFJ8 competed?
The extent of competition for SPE2DR26FCFJ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award